ArticleCancers2020
TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- Sexually distinct multi-omic responses to progressive endurance exercise training in the rat lung.American journal of respiratory cell and molecular biology · 2026Article
- Genetic Prediction of Erectile Dysfunction Caused by Statins Among Malaysian Cardiac Patients.International journal of molecular sciences · 2025Article
- Interfacial cfDNA Enrichment and Amplification with On-Chip Thermoplasmonics for Highly Sensitive Cancerous Liquid Biopsy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- [Gender medicine in lung diseases].Chirurgie (Heidelberg, Germany) · 2024Review
- Article
- Gender oncology: recommendations and consensus of the Italian Association of Medical Oncology (AIOM).ESMO open · 2024Article
- Lung cancer in females-sex-based differences from males in epidemiology, biology, and outcomes: a narrative review.Translational lung cancer research · 2024Review
- Molecular Subtypes and Prognostic Models for Predicting Prognosis of Lung Adenocarcinoma based on MiRNA-related Genes.Current medicinal chemistry · 2024Article
- Establishment of a prognostic signature for patients with advanced lung squamous cell carcinoma based on tumor-infiltrating immune cells.Translational cancer research · 2023Article
- Gender Differences in Oxidative Stress in Relation to Cancer Susceptibility and Survival.Antioxidants (Basel, Switzerland) · 2023Review
- Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific.BMC pulmonary medicine · 2023Article
- Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten loss.Cell death & disease · 2022Article
- Sex dimorphism in response to targeted therapy and immunotherapy in non-small cell lung cancer patients: a narrative review.Translational lung cancer research · 2022Review
- Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.Thoracic cancer · 2022Article
- An efficient five-lncRNA signature for lung adenocarcinoma prognosis, with AL606489.1 showing sexual dimorphism.Frontiers in genetics · 2022Article
- Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation.BMC pulmonary medicine · 2021Article
- Transcriptomic heterogeneity of driver gene mutations reveals novel mutual exclusivity and improves exploration of functional associations.Cancer medicine · 2021Article
- Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.Cancer medicine · 2021Article
- How to Better Understand the Influence of Host Genetics on Developing an Effective Immune Response to Thoracic Cancers.Frontiers in oncology · 2021Review
- A Novel Model Based on Genomic Instability-Associated Long Non-Coding RNAs for Predicting Prognosis and Response to Immunotherapy in Patients With Lung Adenocarcinoma.Frontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Lung cancer poses the greatest cancer-related death risk and males have poorer outcomes than females, for unknown reasons. Patient sex is not a biological variable considered in lung cancer standard of care. Correlating patient genetics with outcomes is predicted to open avenues for improved management. Using a bioinformatics approach across non-small cell lung cancer (NSCLC) subtypes, we identified where patient sex, mutation of the major tumor suppressor gene, Tumour protein P53 (TP53), and immune signatures stratified outcomes in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), among datasets of The Cancer Genome Atlas (TCGA). We exposed sex and TP53 gene mutations as prognostic for LUAD survival. Longest survival in LUAD occurred among females with wild-type (wt) TP53 genes, high levels of immune infiltration and enrichment for pathway signatures of Interferon Gamma (INF-γ), Tumour Necrosis Factor (TNF) and macrophages-monocytes. In contrast, poor survival in men with LUAD and wt TP53 genes corresponded with enrichment of Transforming Growth Factor Beta 1 (TGFB1, hereafter TGF-β) and wound healing signatures. In LUAD with wt TP5
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.